Thian Kheoh, Ph.D., has served as Tocagen’s vice president of biometrics since August 2017. Dr. Kheoh holds more than 28 years of drug development experience spanning early development through approval. Prior to joining Tocagen, Dr. Kheoh served as senior director at Janssen where he successfully led or had a significant role in the approval of five oncology drugs, including ZYTIGA®, YONDELIS®, VELCADE®, SYLVANT® and DARZALEX®. Previous to Janssen, Dr. Kheoh was vice president of biometrics at Cougar Biotechnology, Inc (acquired by Johnson & Johnson) where he was responsible for the statistical design of pivotal trials for ZYTIGA, which achieved peak annual sales of over $2 billion; and senior director at Biogen Idec, where he played a key role in expanding indications for RITUXAN® and the development of future oncology products. Before Biogen Idec, he was an associate director at TAP Pharmaceuticals Inc (joint venture between Abbott and Takeda) and Warner Lambert/Parke-Davis (acquired by Pfizer). Before joining the biopharmaceutical industry, Dr. Kheoh was an assistant professor at the University of Central Florida. Over the course of his career, Dr. Kheoh has co-authored more than fifty publications. Dr. Kheoh received his doctorate in statistics from The University of Western Ontario, and master’s and bachelor’s degrees from the University of Manitoba.